Blood Clots & IBD: Study Quantifies Risk of Venous Thromboembolism During Flares and Remission of Inflammatory Bowel Disease

ClotCare: Blood Clots, Stroke, Heart Attack

Wednesday, October 30, 2024

Home | DVT/PE | Blood Clots | Coumadin/Warfarin | New Patients | Self Testing | Email List | Donate

Pick a Topic: Home New Postings Patient Postings Clinician Postings Join Our Email List Useful Web Links CE Opportunities Training Programs Guidelines DVT & PE Stories Editorial Board Financial Support About ClotCare DVT Coalition Contact Us Find info on a: Specific Medicine or Treatment Type of Medicine or Treatment Condition or Medical Procedure Lab Test Procedure Management Issue ClotCare complies with the HONcode standard for trustworthy health information: verify here. ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.	Study Quantifies Risk of Venous Thromboembolism During Flares and Remission of Inflammatory Bowel Disease Posted by Henry I. Bussey, Pharm.D., FCCP, FAHA March, 2010 Reference: Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. The Lancet, early online publication February 9, 2010 doi: 10.1016/SO140-6736(09)61963-2. Inflammatory bowel disease (IBD) is a well-recognized risk factor for venous thromboembolism (VTE), but investigators from the United Kingdom have generated data recently to help quantify the impact of this risk. Specifically, in a cohort study of 13,756 patients with IBD and 71,672 matched controls, the investigators found that the risk of VTE was 3.4 fold higher in those with IBD, with an absolute risk of 2.6 events per 1,000 patient years. At the time of a flare (identified by a new prescription for glucocorticoid therapy), the risk increased to 8.4 fold increase for an absolute risk of 9.0 events per 1,000 patient years. For patients with this condition - and especially during a flare - it would seem wise to consider whether pharmacologic or mechanical VTE prophylaxis may be warranted (presuming that the individual is not already receiving anticoagulation for a previous event).	Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org. ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters. New Postings: Click here to view full list of new postings
ClotCare Home \| New Postings \| Patient Postings \| Clinician Postings \| Join Our Email List \| Useful Web Links CE Opportunities \| Training Programs \| DVT & PE Stories \| Editorial Board \| Financial Support About ClotCare \| DVT Coalition \| Donate to ClotCare \| Contact Us
Key topics discussed on ClotCare include: Blood Clots \| Deep Vein Thrombosis (DVT) \| Pulmonary Embolism (PE) \| Atrial Fibrillation (A. Fib or AF) \| Heart Attack \| Stroke \| Transient Ischemic Attack (TIA) \| Mini Stroke \| Bleeding Complications \| Vascular Surgery \| Surgical Blood Clot Removal \| Warfarin \| Coumadin \| Lovenox \| Low Molecular Weight Heparin (LMWH) \| Heparin \| Anticoagulants \| Plavix \| Aspirin \| Antiplatelets \| Blood Thinners
Copyright 2000-2018 by ClotCare. All rights reserved. Terms, Conditions, & Privacy \| Image Copyright Information 19260 Stone Oak Parkway, Suite 101 \| San Antonio, TX 78258 \| 210-860-0487 Send comments to webmaster@clotcare.org. Wednesday, October 30, 2024